Tim Van Hauwermeiren Joins RayzeBio’s Board of Directors, Marking a New Era in Radiopharmaceutical Oncology

Conal Cram
3 Min Read

In a significant move for the world of radiopharmaceutical oncology, RayzeBio, Inc. has announced the addition of Tim Van Hauwermeiren, a stalwart in the biopharma realm, to its board of directors. This collaboration might be the catalyst for ushering in transformative treatments in the oncology sector.

Tim Van Hauwermeiren’s Prowess and Achievements

Tim’s reputation precedes him. As the co-founder and CEO of argenx, he’s renowned for “strong execution and innovation,” masterfully leading argenx from its infancy to a global immunology behemoth. His vast experience, spanning over two decades in life sciences, coupled with leadership roles at companies like Ablynx and Procter & Gamble, are testament to his prowess.

Quoting Tim on the recent development, he said:

“RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full potential of this emerging modality.”

RayzeBio’s Vision and Direction

Ken Song, M.D., the President and CEO of RayzeBio, mirrors the excitement surrounding Tim’s appointment. He remarks:

“I am thrilled to welcome Tim to our board of directors. He has been a major force in scaling argenx from a small private company to a global commercial organization bringing forth innovative medicines to help patients. His perspective as a successful operator can help inform us as we continue to build and maintain our leadership in radiopharmaceuticals.”

A Respectful Departure

The induction of Tim also coincides with the exit of Aaron Royston, M.D. from the board. Having served since August 2020, Dr. Royston’s graceful exit comes without any undercurrents of discord. Sharing his sentiments, Dr. Royston mentioned:

“RayzeBio has made tremendous progress in a very short timeframe. I look forward to staying engaged as an investor and continuing to see the company flourish.”

About RayzeBio

RayzeBio stands at the forefront of radiopharmaceutical therapeutics, eyeing to redefine cancer treatment modalities. With their lead program, currently navigating a Phase 3 clinical trial, RayzeBio aims to follow in the footsteps of transformative treatment approaches, much like the advent of antibody drug conjugates in certain cancer treatments.


With the union of Tim Van Hauwermeiren’s vast experience and RayzeBio’s innovative approach, the horizon of radiopharmaceutical oncology looks promising. We invite our readers to comment below, sharing their insights and perspectives on what this collaboration might mean for the future of oncology.

Visit our homepage for more insights on Biotechnology.

Share This Article
Conal is a seasoned tech industry professional and content writer for numerous tech publications. With a strong background in software engineering and digital media development, he's passionate about sharing the latest updates and insights in the tech industry, particularly in artificial intelligence and other disruptive trends. In his spare time he loves a mezze platter and a good film, and if he's not playing Fortnite or spending time with his daughter you can assume he's at the dry slopes!
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *